Conditions: Chronic Plaque-type Psoriasis
Keywords: Moderate to severe chronic plaque-type psoriasis AIN457 dermatology
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 404
Healthy volunteers: no

Brief summary:
The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).

Detailed description:

Arms:
arm 1: Induction with single injection - "Single": secukinumab (AIN457) 150 mg s.c. administered at Week 1, Baseline through Week 12 arm 2: Induction with monthly injections - "Monthly": secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9, Baseline through Week 12 arm 3: Early loading induction - "Early": secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5, Baseline through Week 12 arm 4: Placebo administered at weeks 1, 2, 3, 5, 9, Baseline through Week 12

Interventions: intervention 1: AIN457 intervention 2: AIN457A intervention 3: AIN457A intervention 4: Placebo
Intervention descriptions: intervention 1: None intervention 2: Induction with monthly injections - "Monthly": secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9 intervention 3: Early loading induction - "Early": secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5 intervention 4: Placebo - "Placebo": Placebo administered at weeks 1, 2, 3, 5, 9

Protocol document: